Beta Bionics (NASDAQ:BBNX) Upgraded at Leerink Partnrs

Beta Bionics (NASDAQ:BBNX - Get Free Report) was upgraded by investment analysts at Leerink Partnrs to a "strong-buy" rating in a report issued on Monday,Zacks.com reports. Leerink Partnrs also issued estimates for Beta Bionics' Q4 2024 earnings at ($0.42) EPS, FY2024 earnings at ($1.66) EPS, Q1 2025 earnings at ($0.50) EPS, Q2 2025 earnings at ($0.50) EPS, Q3 2025 earnings at ($0.43) EPS, Q4 2025 earnings at ($0.40) EPS, FY2025 earnings at ($1.82) EPS, FY2026 earnings at ($1.94) EPS, FY2027 earnings at ($2.28) EPS, FY2028 earnings at ($1.42) EPS and FY2029 earnings at ($0.95) EPS.

Several other brokerages also recently weighed in on BBNX. Piper Sandler started coverage on shares of Beta Bionics in a research note on Monday. They set an "overweight" rating and a $26.00 target price on the stock. Bank of America initiated coverage on Beta Bionics in a research report on Monday. They set a "buy" rating on the stock. Robert W. Baird began coverage on Beta Bionics in a research note on Thursday, February 20th. They set a "neutral" rating and a $20.00 target price for the company. LADENBURG THALM/SH SH started coverage on Beta Bionics in a research report on Thursday, February 20th. They issued a "neutral" rating and a $20.00 price target on the stock. Finally, Leerink Partners began coverage on Beta Bionics in a research note on Monday. They issued an "outperform" rating and a $28.00 price objective for the company. Three investment analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus target price of $24.83.

Remove Ads

Beta Bionics Trading Up 5.3 %

NASDAQ:BBNX traded up $1.06 on Monday, hitting $20.97. The stock had a trading volume of 294,220 shares, compared to its average volume of 329,476. Beta Bionics has a 1-year low of $18.67 and a 1-year high of $24.50.

Insiders Place Their Bets

In related news, major shareholder Hadley Harbor Aggre Wellington purchased 1,000,000 shares of the business's stock in a transaction that occurred on Friday, January 31st. The shares were purchased at an average cost of $17.00 per share, for a total transaction of $17,000,000.00. Following the purchase, the insider now directly owns 3,901,599 shares of the company's stock, valued at $66,327,183. The trade was a 34.46 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, insider Mike Mensinger acquired 33,350 shares of the firm's stock in a transaction on Friday, January 31st. The stock was bought at an average price of $17.00 per share, with a total value of $566,950.00. Following the purchase, the insider now directly owns 59,019 shares of the company's stock, valued at $1,003,323. This represents a 129.92 % increase in their ownership of the stock. The disclosure for this purchase can be found here.

Beta Bionics Company Profile

Beta Bionics, Inc is a commercial-stage medical device company. It engages in the design, development, and commercialization of solutions for insulin-requiring people with diabetes. The company was founded by Edward R. Damiano on October 21, 2015 and is headquartered in Irvine, CA.